NEWS RELEASES

Date Title
Oct 12, 2018
Summary ToggleINSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies To advance the medical science of pharmaceutical cannabinoids, pioneering company has now committed to supporting seven clinical trials of its proprietary CBD oral solution PHOENIX , Oct. 12, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture Printer Friendly Version
Oct 10, 2018
Summary ToggleINSYS Therapeutics Names New General Counsel PHOENIX , Oct. 10, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the addition of Mark Nance to its senior management team as chief legal officer Printer Friendly Version
Oct 1, 2018
Summary ToggleINSYS Therapeutics Signs Definitive License Agreement with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East PHOENIX , Oct. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has signed a definitive license agreement with Lunatus for Printer Friendly Version
Sep 27, 2018
Summary ToggleINSYS Therapeutics to Present at 2018 Cantor Global Healthcare Conference PHOENIX , Sept. 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari , president and chief executive officer, and Andy Long , Printer Friendly Version
Sep 4, 2018
Summary ToggleINSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Expand Collaboration to Include Clinical Study of Cannabidiol in Early Psychosis PHOENIX , Sept. 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that its clinical development collaboration with the Center for Medicinal Printer Friendly Version
Aug 30, 2018
Summary ToggleFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis PHOENIX , Aug. 30, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Printer Friendly Version
Aug 9, 2018
Summary ToggleINSYS Therapeutics Appoints Elizabeth Bohlen to Board of Directors PHOENIX , Aug. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Elizabeth Bohlen as a new independent member of its Board of Printer Friendly Version
Aug 8, 2018
Summary ToggleINSYS Therapeutics Reports Second Quarter 2018 Results Focus remains on advancing pipeline across cannabinoid and spray platforms PHOENIX , Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids (CBD) and spray technology, today reported Printer Friendly Version
Aug 8, 2018
Summary ToggleINSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation Provisional Financial Settlement Terms Are Consistent with Previous Public Statements and Disclosures PHOENIX , Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray Printer Friendly Version
Jul 27, 2018
Summary ToggleINSYS Therapeutics Receives Complete Response Letter from FDA for Buprenorphine NDA PHOENIX , July 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) regarding the company’s New Drug Application (NDA) for a buprenorphine sublingual spray as a Printer Friendly Version
Jul 25, 2018
Summary ToggleINSYS Therapeutics to Report Second Quarter 2018 Results on Aug. 8 PHOENIX , July 25, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its second quarter 2018 financial results on Wednesday, Aug. Printer Friendly Version
Jun 18, 2018
Summary ToggleINSYS Therapeutics Provides an Update on Its Ongoing Transformation

PHOENIX , June 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reiterated its ongoing efforts to fundamentally transform the company.

Printer Friendly Version
Jun 14, 2018
Summary ToggleEpinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection

PHOENIX , June 14, 2018 (GLOBE NEWSWIRE) -- Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option for receiving a timely dose of epinephrine to avoid a potentially fatal outcome.

Printer Friendly Version
Jun 4, 2018
Summary ToggleINSYS Therapeutics to Present at Jefferies Global Healthcare Conference

PHOENIX , June 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari , president and chief executive officer, and Andy Long , chief

Printer Friendly Version
May 22, 2018
Summary ToggleINSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray

PHOENIX , May 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, confirmed today that an expert panel convened by the U.S.

Printer Friendly Version
May 15, 2018
Summary ToggleINSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts

PHOENIX , May 15, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today issued the following response to the unsealing of the previously filed Qui Tam complaints and

Printer Friendly Version
May 8, 2018
Summary ToggleINSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

PHOENIX , May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has agreed to an exclusive license partnership with Lunatus for

Printer Friendly Version
May 8, 2018
Summary ToggleINSYS Therapeutics Reports First Quarter 2018 Results

Cannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS ® revenue continue PHOENIX , May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical

Printer Friendly Version
May 2, 2018
Summary ToggleINSYS Therapeutics to The New York Times / May 2, 2018 Our new management team takes the allegations of past wrongdoing by former employees with the greatest seriousness and has focused extensively on instilling the highest respect for fundamentally sound values among all of the company’s more than 300 current employees. Printer Friendly Version
Apr 27, 2018
Summary ToggleINSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome

Study will evaluate safety and efficacy of company’s CBD product candidate in rare genetic disease characterized by insatiable appetite in children PHOENIX , April 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of

Printer Friendly Version
Apr 26, 2018
Summary ToggleINSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical Trial

Company’s pharmaceutical-grade cannabidiol (CBD) oral solution will be evaluated by UC San Diego/CMCR researchers as potential treatment for symptoms of autism PHOENIX , April 26, 2018 (GLOBE NEWSWIRE) -- NSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and

Printer Friendly Version
Apr 25, 2018
Summary ToggleINSYS Therapeutics to Report First Quarter 2018 Results on May 8

PHOENIX , April 25, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its first quarter 2018 financial results on Tuesday, May 8 ,

Printer Friendly Version
Apr 18, 2018
Summary ToggleINSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device

PHOENIX , April 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance clinical research of dronabinol inhalation using a novel and

Printer Friendly Version
Apr 2, 2018
Summary ToggleINSYS Therapeutics Appoints Trudy Vanhove to Board of Directors

PHOENIX , April 02, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Trudy Vanhove as a new independent member of its Board of

Printer Friendly Version
Mar 19, 2018
Summary ToggleINSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipeline PHOENIX , March 19, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement: The company continues striving to take responsibility for Printer Friendly Version
Mar 8, 2018
Summary ToggleINSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results Foundation to become global leader in pharmaceutical cannabinoids and spray technology established in 2017 through new leadership and acceleration of product pipeline PHOENIX , March 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and Printer Friendly Version
Mar 2, 2018
Summary ToggleINSYS Therapeutics Initiates Phase 3 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Infantile Spasms Pivotal study aims to evaluate safety and efficacy of company’s novel CBD product candidate in rare type of pediatric epilepsy PHOENIX , March 02, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical Printer Friendly Version
Mar 1, 2018
Summary ToggleINSYS Therapeutics Confirms Completion of Founder’s Independent Trust PHOENIX , March 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that company founder John N. Kapoor , Ph.D., has completed the previously Printer Friendly Version
Feb 23, 2018
Summary ToggleINSYS Therapeutics to Report Fourth Quarter 2017 Results on March 8 PHOENIX , Feb. 23, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its fourth quarter and full year 2017 financial results on Printer Friendly Version
Feb 20, 2018
Summary ToggleINSYS Therapeutics to Present at RBC Healthcare Conference PHOENIX , Feb. 20, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari , president and chief executive officer, and Andrew Long , Printer Friendly Version
Feb 9, 2018
Summary ToggleINSYS Therapeutics Addresses Maryland Attorney General’s Motion PHOENIX , Feb. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement in response to a motion filed by the Office of the Maryland Printer Friendly Version
Feb 1, 2018
Summary ToggleINSYS Therapeutics Addresses New York Attorney General’s Complaint PHOENIX , Feb. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement in response to a complaint filed by the New York attorney Printer Friendly Version
Feb 1, 2018
Summary ToggleINSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors PHOENIX , Feb. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Vaseem Mahboob as a new independent member of its board of Printer Friendly Version
Jan 30, 2018
Summary ToggleINSYS Therapeutics Adds Two New Executives to Senior Management Team VP of Human Resources, Carol Summersgill ; VP of Clinical Development, Dr. Ahmed Elkashef PHOENIX , Jan. 30, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today Printer Friendly Version
Jan 3, 2018
Summary ToggleINSYS Therapeutics to Present at J.P. Morgan Healthcare Conference PHOENIX , Jan. 03, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that Saeed Motahari , president and chief executive officer, and Andrew Long , chief financial officer, will present at the 36 th annual J.P. Morgan Healthcare Conference as follows: Date:       Printer Friendly Version